Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029982

Enrollment

Unknown

Registered

2020-02-18

Start date

2020-03-26

Completion date

Unknown

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

COVID-19 group:NA

Healthy people:NA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"; 2. Those without broad-spectrum antibacterial, antifungal, and antiviral treatment; 3. Imaging revealed pneumonia in patients with a diagnosis of pathogen: influenza, CAP / HAP bacterial infection, and fungal infection.

Exclusion criteria

Exclusion criteria: 1. A coma, MODS or death occurred on admission; 2. The estimated survival time is <7 days; 3. The patient's medical history is not detailed and relatives cannot be contacted.

Design outcomes

Primary

Measure	Time frame
Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Metabolomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;	—

Countries

China

Contacts

Public ContactJin Yang

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

whuhjy@sina.com+86 13554361146

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026